Lifeboat Foundation

New research, led by scientists at the University of Cambridge, suggests spontaneous DNA mutations that occur when a baby’s brain is growing in the womb may help explain why so many people develop dementia without having any prior family history with the disease.

A new treatment strategy could increase the success rate of stem cell transplants, according to University of Queensland researchers.

The approach removes the need for donor matching and the use of immunosuppressant drugs to prevent rejection, and could make stem cell treatment accessible to more patients.

UQ Diamantina Institute researcher Dr Jatin Patel said researchers found immunosuppressant drugs had a negative impact on the transplanted stem cells.

Continue reading “New treatment prevents transplant rejection” »

Should there be any ethical or legal boundaries to technologies that enhance humans? I pondered this last week as I read an online article about the recent trials of upper-body “exoskeletons” by production line staff at Volkswagen and at Chrysler-Fiat. These lightweight wearable frames greatly reduce the physical strain of repetitive overhead assembly work, and will be an important industrial enhancement as workforces age.

We tend to think of medical advancement in terms of better cures for diseases and recovery from injury. Enhancement however goes beyond therapy, and extends us in ways that some may argue are unnatural. Some human enhancements are of course also pre-emptive therapeutic interventions. Vaccination is both an enhancement of our immune system, and a therapeutic intervention. However, in cases where there is little preventative justification, what degree of enhancement is acceptable?

We drink coffee expecting our work performance to improve. We accept non-elective operations, breast implants, orthodontic improvements and other interventions which improve our perception of ourselves. We generally accept such enhancements with little question. However devices and drugs that improve athletic performance can lead us to question their legitimacy.

Continue reading “To be – or not to be – an enhanced human” »

Intervene Immune is a company focused on the age-related decline of the immune system, which is known as immunosenescence. Here, Bobby Brooke, CEO of Intervene Immune, discusses the clinical potential of regenerating the thymus as a means of reversing age-related immune system decline.

Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union, New York City. This was a conference designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights.

Continue reading “The Potential of Thymus Regeneration” »

To understand the mechanisms by which molecules act in cells, or the effects of drugs on them, it would be ideal to be able to track individual molecules, including where in the cell they are located and what modifications they undergo when conditions in the cell change. However, this has proven difficult with existing technologies, particularly given the amount of time required to perform such monitoring.

A research team centered at Osaka University, in collaboration with RIKEN, has developed a system that can overcome these difficulties by automatically searching for, focusing on, imaging, and tracking single molecules within living cells. The team showed that this approach could analyze hundreds of thousands of single molecules in hundreds of cells in a short period, providing reliable data on the status and dynamics of molecules of interest.

Continue reading “Artificial intelligence aids automatic monitoring of single molecules in cells” »

Anversa, who according to publications was most recently affiliated with the Cardiocentro Ticino and University of Zurich, could not be reached for comment. An email to his address at Cardiocentro Ticino bounced back. A number of Anversa’s co-authors either did not immediately respond to a request for comment, or declined.

“We are committed to upholding the highest ethical standards and to rigorously maintaining the integrity of our research,” Harvard and the Brigham said. “Any concerns brought to our attention are reviewed in accordance with institutional policies and applicable regulations.”

Anversa received his MD from the University of Parma in Italy and gained prominence as a stem-cell researcher at New York Medical College in Valhalla, N.Y., where he worked before moving to Harvard Medical School and the Brigham in 2007. Anversa became a full professor in 2010, joined in that rank that year by Dr. José Baselga, who earlier this fall resigned his post at Memorial Sloan Kettering Cancer Center amid reports that he failed to adequately disclose financial conflicts of interest.

Continue reading “Harvard and the Brigham call for 31 retractions of cardiac stem cell research” »

Shanghai Gensource Medical Appliances, will distribute Tel Aviv based Micromedic’s product to the group’s customers in 25 cities across China and more than 8,000 hospitals and medical centers.

A new study argues that more than half of Americans could be identified by name if all you had to start with was a sample of their DNA and a few basic facts, such as the region where they live and about how old they might be.

New Aubrey interview.

Today we explore human longevity and life extension efforts focused on adding healthy years to a person’s lifespan, and even reversing the aging process.

Continue reading “Life Extension & Human Longevity with Dr. Aubrey de Grey on MIND & MACHINE” »